CLPT, si, mi chat solo quiere complacerme, no sé si en este análisis de competencia se habrá dejado algo. Según lo promtee me da cifras variadas que me hacen complicado valorar el stock. También temo que entre un medtornic, un siemens, un blackrock, pero tendrían que hacer el mismo proceso largo de fda, y luego el proceso de las pharmas en adoptarlo...el tiempo dirá, sin duda es interesante, me gusta leer tu visión, saludos!relacionada, CADL, he visto esto en twitter: Jefferies 2025 Healthcare Conference 17 novThe last few minutes I want to spend to talk about CAN-3110. This is a different mechanism of action. It's also a viral immunotherapy, but it's a true oncolytic virus. It's replication competent HSV. Unlike everybody else that has deleted the so-called ICP34.5 gene, so think of Imlygic, think of Replimune programs and others, everybody has knocked out the 34.5 gene. Why? Because it is associated with neurotoxicity. That makes a lot of sense. However, if you do that, you create a virus that's less effective. What we've done is we have inserted one copy of this gene but put it under the control of a tumor-specific promoter, which is the Nestin promoter. Nestin plays a role in embryogenesis. It's completely absent from the healthy adult brain, but it's upregulated in every glioblastoma. We went for recurrent glioblastoma, the graveyard of industry where everything has failed. I'll show you just one example. Here we have a typical disease course of a patient with recurrent high-grade glioma. You see the initial lesion. The patient went for a subtotal resection. At some point, and that's always the case, unfortunately, there's recurrence of the disease. There is rapid progression. When you look at day minus 14, the patient underwent actually a second resection.Two weeks later, the tumor was growing again. These patients are going to die within weeks, definitely not more than a month. On day zero, we gave a single injection of CAN-3110 into the tumor. You can see the timelines are changing. Three months after that, there appears to be, again, tumor progression on imaging. We took biopsies, and it appeared that it was largely pseudo-progression. We were replacing tumor cells by immune cells. The patient went for another debulking at day 96. The patient was still alive. After that, the patient was considered to be cured. You see on the right, day 630, there is a very long timeline here. You see this big empty space. The patient lived a completely normal life until she died in a car accident while she was even not driving. This is just one example. We just announced just a few weeks ago that even in the patients who have received a single injection, we have a patient who's still alive after 59.2 months, the other 42.4 months. These are extreme timelines. We're starting to see long-term survivors even after a single injection. Now we've asked the question, what would happen if you give multiple injections? We went up to six injections. This is ongoing. We see very encouraging results. We're starting to see the first long-term survivors. We just published data where we took serial biopsies from the brain. I mean, this is pretty amazing. This has been never done before. We ended up on the cover of Science Translational Medicine just a few weeks ago. What you can see here in red, you see this big tumor. In the middle, you see the yellow area, which represents necrosis, cell death in these tumor cells. You see four green dots. These are the four injections of CAN-3110. This was a pathological complete response, which I think has never been described in recurrent glioblastoma. We'll have an update about this in Q4 next year, where we're starting to look at long-term survival for CAN-3110
